Citius Oncology, Inc.

CTOR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Assets
Cash & Equivalents $3.9M $112 — — —
Accounts Receivable — — — — —
Inventory $22.3M $8.3M — — —
Total Current Assets $27.5M $11.0M $58.2K $377.3K $126.4K
Property, Plant & Equipment — — — — —
Goodwill — — — — —
Intangible Assets (Excl. Goodwill) — — — — —
Total Assets $100.9M $84.4M $72.6M $68.2M $126.4K
Liabilities
Accounts Payable $13.2M $3.7M $1.3M — —
Total Current Liabilities $49.5M $32.7M $2.0M $31.8K $136.5K
Long-Term Debt — — — — —
Total Liabilities $56.1M $38.2M $22.2M $67.8M $136.5K
Stockholders' Equity
Retained Earnings $-64.0M $-39.3M $-2.0M $345.3K $-10.1K
Total Stockholders' Equity $44.9M $46.1M $-2.0M $345.5K $-10.1K